CEA, DMTS, SPI, Neurovascular Unit Research & Therapeutic Innovation Laboratory, Paris-Saclay University, CEDEX 91191 Gif-sur-Yvette, France.
Center of Excellence of Precision Medicine, Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
Int J Mol Sci. 2024 May 17;25(10):5449. doi: 10.3390/ijms25105449.
Hypoxic-ischemic encephalopathy (HIE) is a major cause of newborn brain damage stemming from a lack of oxygenated blood flow in the neonatal period. Twenty-five to fifty percent of asphyxiated infants who develop HIE die in the neonatal period, and about sixty percent of survivors develop long-term neurological disabilities. From the first minutes to months after the injury, a cascade of events occurs, leading to blood-brain barrier (BBB) opening, neuronal death and inflammation. To date, the only approach proposed in some cases is therapeutic hypothermia (TH). Unfortunately, TH is only partially protective and is not applicable to all neonates. This review synthesizes current knowledge on the basic molecular mechanisms of brain damage in hypoxia-ischemia (HI) and on the different therapeutic strategies in HI that have been used and explores a major limitation of unsuccessful therapeutic approaches.
缺氧缺血性脑病(HIE)是新生儿期由于缺氧性血流不足导致的主要新生儿脑损伤原因。25%至 50%发生 HIE 的窒息婴儿会在新生儿期死亡,约 60%的幸存者会发展出长期的神经功能障碍。从损伤后的最初几分钟到几个月,一系列事件发生,导致血脑屏障(BBB)开放、神经元死亡和炎症。迄今为止,一些病例中唯一提出的方法是治疗性低温(TH)。不幸的是,TH 只是部分保护,并不适用于所有新生儿。本综述综合了目前关于缺氧缺血(HI)中脑损伤的基本分子机制以及在 HI 中使用的不同治疗策略的知识,并探讨了不成功的治疗方法的一个主要局限性。